In adults with grade 3–4 astrocytoma, BRAF/MEK-targeted therapy was associated with improved overall survival (Fig. 4f) compared with grade 3–4 patients who did not receive targeted therapy, suggesting targeted therapy has the ability to impact disease trajectory. This evidence concerns the gene MAP2K7 and astrocytoma (excluding glioblastoma).